For research use only. Not for therapeutic Use.
Lonafarnib(Cat No.:I002472)is a farnesyltransferase inhibitor (FTI) developed to block the post-translational farnesylation of proteins, particularly those involved in cellular signaling pathways, such as the Ras protein. By inhibiting farnesylation, lonafarnib disrupts cancer cell growth and proliferation, making it a potential anti-cancer therapy. It has also gained attention for its role in treating Hutchinson-Gilford progeria syndrome (HGPS), a rare genetic condition causing premature aging, by preventing the buildup of toxic progerin proteins. Lonafarnib is being explored for its broader therapeutic applications in cancer and progeroid syndromes.
Catalog Number | I002472 |
CAS Number | 193275-84-2 |
Synonyms | Lonafarnib; Sch66336; 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[1,2]cyclohepta[2,4-b]pyridin-11-yl]piperidin-1-yl]-2-oxoethyl]piperidine-1-carboxamide |
Molecular Formula | C₂₇H₃₁Br₂ClN₄O₂ |
Purity | 98% |
Target Protein | P49356,P49354 |
Solubility | in DMSO > 10 mM |
Appearance | Solid |
Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
IC50 | IC50: 1.9 nM (H-ras), 5.2 nM (K-ras), 2.8 nM (N-ras) |
IUPAC Name | 4-[2-[4-[(2R)-6,15-dibromo-13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl]piperidin-1-yl]-2-oxoethyl]piperidine-1-carboxamide |
InChI | InChI=1S/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1 |
InChIKey | DHMTURDWPRKSOA-RUZDIDTESA-N |
SMILES | C1CN(CCC1CC(=O)N2CCC(CC2)[C@@H]3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N |
Reference | 1. Expert Opin Investig Drugs. 2012 Jul;21(7):1043-55. doi: <br> 2. Expert Opin Investig Drugs. 2006 Jun;15(6):709-19. |